(一) 股东总数： 2023 年半年度报告 (三) 战略投资者或一般法人因配售新股成为前十名股东 □适用 √不适用 □适用 √不适用 2023 年半年度报告 2023 年半年度报告 (一) 企业债券 说明： （1）还本付息方式：按年付息，最后一次利息随本金一起兑付。 （2）交易场所：银行间债券市场。 （3）不存在终止上市交易的风险。 3. 信用评级结果调整情况 2023 年半年度报告 (四) 公司报告期内合并报表范围亏损超过上年末净资产 10% √适用 □不适用 单位：元 币种：人民币 二、可转换公司债券情况 2023 年半年度报告 一、 审计报告 2023 年半年度报告 2023 年半年度报告 | --- | --- | --- | --- | |-------------------------------------------|----------|------------------------------|---------------------------------------------------------| | 编制单位：上海现代制药股份有限公司 \n项目 | 附注 | 2023 年 ...

2023 年第一季度报告 证券代码：600420 证券简称：国药现代 债券代码：110057 债券简称：现代转债 上海现代制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 第一季度财务报表是否经审计 (一)主要会计数据和财务指标 2023 年第一季度报告 the state of the submit and the submit and the submit of the submit of the submit | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|-----------------------| | | 单位：元 币种：人民币 | | 项目 | 本期金额 | | 非流动资产处置损益 | 51,166.64 | | 计入当期损益的政府补助，但与公司正常经营业务密切相关，符合国家政 ...

十二、报告期内的内部控制制度建设及实施情况 54 / 208 √适用 □不适用 公司聘请天健事务所对公司内部控制的有效性进行审计，并出具了内部控制审计报告。公司 《2022 年度内部控制审计报告》于 2023 年 3 月 30 日在上海证券交易所网站（www.sse.com.cn） 披露。 是否披露内部控制审计报告：是 内部控制审计报告意见类型：标准的无保留意见 2022 年年度报告 （一）属于环境保护部门公布的重点排污单位的公司及其主要子公司的环保情况说明 √适用 □不适用 56 / 208 √适用 □不适用 报告期内，公司下属环保重点监控单位配套的环保治理设施，包括厂内污水处理设施及大气 排口终端处理设施等，均运行正常。且各单位持续针对污水、废气、危废设施开展提升建设，其 中国药现代浦东制造中心对新污水站各个池体废气加盖、收集，并完成废气管道、风机接入工作， 确保污水站废气排放达标；国药威奇达新增沼气锅炉，达标排放同时回收热量，减少外购蒸汽消 耗。 对于已建环保设施，各单位均已落实专人负责运行和监测，部分单位委托第三方专业机构开 展设施运行管理，确保环保设施的正常运行及达标排放。所有下属环保重点监控单位均 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：600420 证券简称：国药现代 债券代码：110057 债券简称：现代转债 上海现代制药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|------------------|--------------------------------------|------------------|-------------- ...

2022 年半年度报告 公司代码：600420 公司简称：国药现代 转债代码：110057 转债简称：现代转债 上海现代制药股份有限公司 2022 年半年度报告 1 / 148 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事 刘勇 工作原因 李晓娟 三、 本半年度报告未经审计。 四、 公司负责人周斌、主管会计工作负责人郝超峰及会计机构负责人（会计主管人员）高蕾声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司半年度无利润分配或资本公积转增股本预案。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，投资 者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 七、 是否存在被控股股东及其关联方非经 ...

2022 年第一季度报告 单位：元 币种：人民币 1/15 证券代码：600420 证券简称：国药现代 债券代码：110057 债券简称：现代转债 上海现代制药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 项目 本报告期 本报告期比上年同期增减变动幅度(%) | --- | --- | --- | --- | |-----------------------------------------------|-------------------|-------------------|--------------------- ...

Financial Performance - The company achieved a net profit attributable to shareholders of 568,280,771.91 yuan for the year 2021, with a distributable profit balance of 2,126,519,988.53 yuan as of the end of the reporting period[6]. - The company's operating revenue for 2021 was ¥13,944,948,270.25, representing an increase of 11.06% compared to ¥12,556,281,595.67 in 2020[23]. - Net profit attributable to shareholders for 2021 was ¥568,280,771.91, a decrease of 12.41% from ¥648,792,627.72 in 2020[25]. - The net cash flow from operating activities increased by 7.66% to ¥1,679,662,393.87 in 2021, compared to ¥1,560,179,011.64 in 2020[25]. - The total assets at the end of 2021 were ¥19,069,961,392.45, up 4.49% from ¥18,250,454,785.72 at the end of 2020[25]. - Basic earnings per share for 2021 were ¥0.5534, down 12.41% from ¥0.6318 in 2020[27]. - The weighted average return on net assets decreased to 6.80% in 2021, down from 8.25% in 2020, a reduction of 1.45 percentage points[27]. - The company reported a net profit of ¥220,707,073.48 in Q1 2021, with a decline in Q4 resulting in a negative net profit of -¥63,171,056.34[32]. - The total non-recurring gains and losses for 2021 amounted to ¥71,161,732.93, compared to ¥132,482,398.84 in 2020[33]. Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan per ten shares (including tax) to all shareholders based on the total share capital on the equity registration date[6]. - The company has 1,026,964,555 shares as of December 31, 2021, which will be used as the basis for the cash dividend distribution[189]. Research and Development - The company invested 589 million RMB in R&D, an increase of 18.09% compared to the previous year, to enhance innovation capabilities[53]. - The company launched 64 research projects during the reporting period, with 56 projects undergoing consistency evaluation, resulting in 4 products passing the evaluation[39]. - The company applied for 44 new patents, including 17 invention patents, and received 54 new patent authorizations during the reporting period[39]. - The company is focusing on five key therapeutic areas: anti-infective drugs, anti-tumor drugs, anesthetic and psychotropic drugs, cardiovascular drugs, and metabolic and endocrine drugs[46]. - The company is actively exploring innovative drug development and has introduced 4 new products through licensing agreements[104]. - The company is focusing on high-end generic drugs and modified new drugs as primary R&D directions[104]. - The company has completed consistency evaluations for several products, including injection of cefotaxime sodium (1.0g) and others[111]. - The company plans to continue increasing R&D investment to enhance innovation capabilities for high-quality development[117]. Sales and Market Performance - In 2021, the company achieved a sales growth of 13.90% year-on-year, with international sales reaching 2.841 billion yuan, a year-on-year increase of 23.52%[39]. - The company achieved a total revenue of 13.94 billion RMB in 2021, representing a year-on-year growth of 11.06%[50]. - The sales revenue from the company's intermediates and APIs increased its revenue share by 1.89 percentage points year-on-year[46]. - The sales revenue of formulation products grew by 7.24%, with cardiovascular products like sustained-release nifedipine increasing by 19.35%[46]. - The company reported a 60% increase in sales volume for injectable ceftriaxone sodium due to successful bidding in centralized procurement[46]. - The company’s brand strategy has strengthened its market presence, with several products receiving international certifications, including FDA and CEP[50]. - The company is actively expanding its product line in the health sector and exploring various sales models, including online and offline channels[122]. Operational Efficiency - The company implemented measures to improve cash flow management, resulting in a notable increase in cash received from sales in Q3 2021[32]. - The company is implementing a strict procurement management system to enhance efficiency and reduce costs through centralized procurement[46]. - The company is advancing its production automation and quality control through the upgrade of information systems like MES, LIMS, and ERP[46]. - The company aims to enhance operational efficiency and promote strategic development through continuous technological innovation and structural optimization[46]. - The company has established a comprehensive industrial chain covering raw materials, intermediates, and finished products, enhancing cost advantages[50]. Governance and Compliance - The company has a standard unqualified audit report issued by Tianjian Accounting Firm[5]. - All directors attended the board meeting, ensuring the integrity of the annual report[5]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its forward-looking statements[7]. - The company has established a performance management system linking the results of annual assessments of senior management to their compensation[145]. - The company has implemented a comprehensive information disclosure management system to ensure timely and fair disclosure of information[145]. - The company has established specialized committees under the board, including strategy and investment, audit and risk management, nomination, and compensation committees[145]. - The company has maintained effective internal control over financial reporting, with no significant deficiencies identified in 2021[197]. Environmental and Social Responsibility - The company has actively engaged in environmental protection, with specific measures in place to monitor and manage pollutant emissions across its operations[200]. - The company has committed to fulfilling social responsibilities and balancing the interests of shareholders, employees, and society[145]. - Environmental protection is prioritized, with the company aiming to enhance its environmental management and compliance capabilities[142]. Market Challenges and Future Outlook - The company anticipates continued growth in sales due to an increase in the proportion of raw material drug sales, which may extend the collection period[78]. - The company is addressing supply chain risks by enhancing resource integration and improving procurement efficiency[142]. - The company recognizes potential risks from industry policies and market dynamics, and is actively researching and adapting to these changes[142]. - The company anticipates intensified market competition due to ongoing drug procurement policies and the acceleration of drug consistency evaluations[142].

2021 年第三季度报告 证券代码：600420 证券简称：国药现代 债券代码：110057 债券简称：现代转债 上海现代制药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|--------------------------------------|-----------------------------|--------- ...

2021 年半年度报告 公司代码：600420 公司简称：国药现代 债券代码：110057 债券简称：现代转债 上海现代制药股份有限公司 2021 年半年度报告 1 / 168 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人周斌、主管会计工作负责人祖敬及会计机构负责人（会计主管人员）高蕾声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2021年半年度无利润分配或资本公积转增股本预案。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，投资 者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 ...

2021 年第一季度报告 公司代码：600420 公司简称：国药现代 债券代码：110057 债券简称: 现代转债 上海现代制药股份有限公司 2021 年第一季度报告 1 / 23 2021 年第一季度报告 目录 | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 一、重要提示 .............................................................................................................................................3 | | 二、公司基本情况 ................................................................ ...